The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million. In the deal, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback